Healthcare
UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF(CBUS)
Live Price
Offline$1.27
+2.85% today
1Y Change
-11.04%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $70.00M
- Revenue Growth
- -14.6%
- EPS Growth
- +74.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF (CBUS) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.26 and down 11.0% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -14.6%, EPS growth of +74.3%, a dividend yield of 0.0%. What stands out right now is revenue -14.6%, EPS +74.3%, free cash flow +13.1% with operating margin -2429.6% and ROIC -30.3%. Valuation already assumes a fairly strong business story at price/sales 19.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CBUS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-14.6% vs +7.6% peer median
Operating Margin
Below sector median
-2429.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -14.6% and EPS is at +74.3%, with operating margin around -2429.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -7.1% | -2.1% | -12.8% |
2026 Mar 17, 2026 | +2.3% | -24.7% | -26.4% | -60.9% |
2025 Nov 13, 2025 | -7.3% | -2.4% | +0.8% | +28.8% |
Benchmark Edge
CBUS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CBUS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CBUS Max Drawdown
-70.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CBUS and SPY.
Company Overview
UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF
NASDAQ
Cibus Inc., a leading company within the bioscience sector, focuses on developing and commercializing sustainable agricultural solutions. The primary function of Cibus lies in its innovative gene-editing technology aimed at enhancing plant traits, thereby improving crop yield, resilience, and overall sustainability. Cibus leverages its proprietary Rapid Trait Development System (RTDS) to address food security and agricultural efficiency, making it a key player in the production of non-GMO, improved crop varieties. These advancements cater to a variety of industries, notably agriculture and food production, promoting sustainable practices aligned with global environmental strategies. Headquartered in the biotech hub of San Diego, Cibus collaborates with seed companies and agricultural producers worldwide, providing solutions that respond to the ongoing demand for increased agricultural productivity without compromising environmental concerns. By playing a crucial role in modern crop management, Cibus Inc. supports the drive towards a more sustainable and efficient agricultural economy, contributing significantly to the evolving landscape of global food supply and security.
- Leadership
- Dr. Peter R. Beetham B.Sc., Ph.D.
- Employees
- 118
- Street Address
- 6455 Nancy Ridge Drive
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 19.3
- Price/Book
- 32.3
Growth
- Revenue
- -14.6%
- EPS
- +74.3%
- Free Cash Flow
- +13.1%
Profitability
- Gross Margin
- 23.9%
- Operating Margin
- -2429.6%
- Net Margin
- -3492.3%
- ROE
- -236.8%
- ROIC
- -30.3%
Balance Sheet
- Debt/Equity
- 12.28
- Current Ratio
- 0.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.